Pharmacyclics Shares Popped: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharma company Pharmacyclics (Nasdaq: PCYC  ) were hopping today, gaining as much as 12% in intraday trading on heavier-than-average volume.

So what: After yesterday's close, Pharmacyclics announced data from the phase IB/II study on its Bruton's tyrosine kinase inhibitor. While the title of the company's presentation -- " Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study" -- doesn't make it sound like a beach read, investors seemed to enjoy it thanks to the encouraging results regarding Pharmacyclics' treatment.

Now what: With most of its treatments still in early stages, Pharmacyclics investors have a ways to go before they'll see anything hitting the bottom line at this company. That doesn't mean that the stock will be sleepy though. News like yesterday's that shows progress (or lack thereof) through the regulatory gauntlet will continue to whip the stock around.

Want to keep up to date on Pharmacyclics? Add it to your watchlist.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1504153, ~/Articles/ArticleHandler.aspx, 4/19/2014 10:58:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement